Cascade Investment Advisors Inc. Boosts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cascade Investment Advisors Inc. boosted its position in Johnson & Johnson (NYSE:JNJFree Report) by 2.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,142 shares of the company’s stock after purchasing an additional 235 shares during the quarter. Cascade Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $1,467,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. IFS Advisors LLC raised its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson in the third quarter valued at $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC increased its position in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the last quarter. Finally, Activest Wealth Management acquired a new position in Johnson & Johnson in the third quarter valued at about $40,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 1.1 %

Shares of Johnson & Johnson stock opened at $152.78 on Friday. The company has a fifty day simple moving average of $147.73 and a 200-day simple moving average of $156.10. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $367.82 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.29 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.25%. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Guggenheim boosted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Wolfe Research assumed coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $170.44.

Get Our Latest Analysis on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.